Dyadic to Present at the Sanders Morris Harris Investor Growth Conference on October 23, 2006 at 10:00 a.m. EDT
17 Octobre 2006 - 11:52PM
Business Wire
Dyadic International, Inc. (AMEX:DIL), a biotechnology company,
announced today that Mark Emalfarb, Dyadic�s President and Chief
Executive Officer, will make a presentation at the Sanders Morris
Harris Investor Growth Conference to be held in New York City at
the Omni Berkshire Place, 21 East 52nd Street at Madison Avenue, on
October 23-24, 2006. Mr. Emalfarb's presentation is scheduled for
October 23 at 10:00 a.m. EDT. A simultaneous webcast of the
presentation may be accessed by clicking the webcast link at
www.dyadic.com. A replay will be available for 30 days at the same
internet address. Mr. Emalfarb plans to discuss Dyadic's progress
in the development of its proprietary enabling platform
technologies, which are broadly applicable for the discovery,
development and large-scale production of new, improved and/or more
affordable products in three core business areas: Biorefineries,
including the Company�s recent advances in the development of its
patented and proprietary enzyme mixtures to make abundant low-cost
sugars from agricultural plant materials. Sugars can be used in
place of petroleum to produce ethanol, plastics and polymers in a
variety of manufacturing and refining processes. Biosciences,
updating Dyadic's efforts to leverage its patented C1 Host
Technology to facilitate more efficient discovery, development and
production of new, improved and/or more affordable human
antibodies, as well as other protein drugs; and, Enzymes, detailing
the Company�s progress in expanding its Enzyme Business beyond
textiles to larger and more profitable markets including pulp and
paper and animal feed. About Dyadic Dyadic International, Inc.,
based in Jupiter, Florida, with operations in the United States of
America, Hong Kong and mainland China, Poland and The Netherlands,
is engaged in the development, manufacture and sale of biological
products using a number of proprietary fungal strains to produce
enzymes and other biomaterials, principally focused on a system for
protein production based on the patented Chrysosporium lucknowense
fungus, known as C1. Dyadic is applying its technologies to produce
enzymes for use in converting various agricultural products (e.g.
corn) and waste products (e.g. switch grass, wheat straw, sugar
cane bagasse, etc.) into fermentable sugars, which can then be used
in the production of traditional and cellulosic ethanol as well as
other products currently derived from petroleum. Dyadic's C1
technology also is being developed to facilitate the discovery,
development and large-scale production of human antibodies and
other high-value therapeutic proteins. Dyadic currently sells more
than 45 liquid and dry enzyme products to more than 200 industrial
customers in approximately 50 countries for the textile, pulp &
paper, animal feed, alcohol, starch, and food and beverage
industries. Cautionary Statement for Forward-Looking Statements
Certain statements contained in this press release are
"forward-looking statements." These forward-looking statements
involve risks and uncertainties that could cause our actual
results, performance or achievements to be materially different
from any future results, performance or achievements expressed or
implied by such forward-looking statements. For a discussion of
these risks and uncertainties, please see our filings from time to
time with the Securities and Exchange Commission, which are
available free of charge on the SEC's web site at
http://www.sec.gov, including our Annual Report on Form 10-KSB for
the year ended December 31, 2005, and our subsequent filings with
the SEC. Except as required by law, we expressly disclaim any
intent or obligation to update any forward-looking statements.
Dyadic International, Inc. (AMEX:DIL), a biotechnology company,
announced today that Mark Emalfarb, Dyadic's President and Chief
Executive Officer, will make a presentation at the Sanders Morris
Harris Investor Growth Conference to be held in New York City at
the Omni Berkshire Place, 21 East 52nd Street at Madison Avenue, on
October 23-24, 2006. Mr. Emalfarb's presentation is scheduled for
October 23 at 10:00 a.m. EDT. A simultaneous webcast of the
presentation may be accessed by clicking the webcast link at
www.dyadic.com. A replay will be available for 30 days at the same
internet address. Mr. Emalfarb plans to discuss Dyadic's progress
in the development of its proprietary enabling platform
technologies, which are broadly applicable for the discovery,
development and large-scale production of new, improved and/or more
affordable products in three core business areas: -- Biorefineries,
including the Company's recent advances in the development of its
patented and proprietary enzyme mixtures to make abundant low-cost
sugars from agricultural plant materials. Sugars can be used in
place of petroleum to produce ethanol, plastics and polymers in a
variety of manufacturing and refining processes. -- Biosciences,
updating Dyadic's efforts to leverage its patented C1 Host
Technology to facilitate more efficient discovery, development and
production of new, improved and/or more affordable human
antibodies, as well as other protein drugs; and, -- Enzymes,
detailing the Company's progress in expanding its Enzyme Business
beyond textiles to larger and more profitable markets including
pulp and paper and animal feed. About Dyadic Dyadic International,
Inc., based in Jupiter, Florida, with operations in the United
States of America, Hong Kong and mainland China, Poland and The
Netherlands, is engaged in the development, manufacture and sale of
biological products using a number of proprietary fungal strains to
produce enzymes and other biomaterials, principally focused on a
system for protein production based on the patented Chrysosporium
lucknowense fungus, known as C1. Dyadic is applying its
technologies to produce enzymes for use in converting various
agricultural products (e.g. corn) and waste products (e.g. switch
grass, wheat straw, sugar cane bagasse, etc.) into fermentable
sugars, which can then be used in the production of traditional and
cellulosic ethanol as well as other products currently derived from
petroleum. Dyadic's C1 technology also is being developed to
facilitate the discovery, development and large-scale production of
human antibodies and other high-value therapeutic proteins. Dyadic
currently sells more than 45 liquid and dry enzyme products to more
than 200 industrial customers in approximately 50 countries for the
textile, pulp & paper, animal feed, alcohol, starch, and food
and beverage industries. Cautionary Statement for Forward-Looking
Statements Certain statements contained in this press release are
"forward-looking statements." These forward-looking statements
involve risks and uncertainties that could cause our actual
results, performance or achievements to be materially different
from any future results, performance or achievements expressed or
implied by such forward-looking statements. For a discussion of
these risks and uncertainties, please see our filings from time to
time with the Securities and Exchange Commission, which are
available free of charge on the SEC's web site at
http://www.sec.gov, including our Annual Report on Form 10-KSB for
the year ended December 31, 2005, and our subsequent filings with
the SEC. Except as required by law, we expressly disclaim any
intent or obligation to update any forward-looking statements.
Dyadic (AMEX:DIL)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024
Dyadic (AMEX:DIL)
Graphique Historique de l'Action
De Juin 2023 à Juin 2024